Gynecologic Cancers

Adjuvant radiation therapy provides a local control benefit in stage III endometrial carcinoma patients, as strongly suggested in retrospective and prospective series.

The routine use of adjuvant radiation therapy in stage III endometrial cancer patients is not supported by the current literature and should not be employed universally in this group of patients.

Certain malignancies may possess a common and targetable matrix response, which affects disease pathogeneis, according to a study in Cancer Discovery.

New research examines the mechanisms underlying why most patients with high-grade serous ovarian cancer develop resistance to PARP inhibitors.

Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer.

Optical coherence tomography and multispectral fluorescence imaging have demonstrated promising results in the early detection of ovarian cancer.

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches.

A meta-analysis finds that postmenopausal bleeding occurs in approximately 90% of women with endometrial cancer.

Sorafenib combined with topotecan and then continued as maintenance therapy offered a significant improvement in survival outcomes in women with platinum-resistant ovarian cancer.

Apatinib combined with etoposide offers promising efficacy in patients with platinum-resistant ovarian cancer.

The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.

The intratumoral vasculature of high-grade serous ovarian cancer does not appear to undergo significant changes during disease progression.

Recent use of aspirin or NSAIDs is associated with improved ovarian cancer–specific survival.

In an interview with Cancer Network, Lorraine Drapek describes a multidisciplinary program at MGH to support vaginal and sexual health post RT for GI and gynecologic malignancies.

The approval of PARP inhibitors has caused a paradigm shift in ovarian cancer management and a challenge for clinicians, who must decide how best to use these agents in individualized treatment.

In women with ovarian cancer, those with early life adversity and anxiety had more dysregulation of cortisol, suggesting they may be at risk for more negative outcomes.

New data suggest adding bevacizumab to chemotherapy may prolong PFS in patients with recurrent ovarian cancer.

The noninferiority of neoadjuvant chemotherapy vs upfront surgery could not be confirmed with regard to overall survival in patients with ovarian, tubal, and peritoneal cancers.

A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.

Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.

A personalized cancer vaccine was well tolerated and was capable of inducing antitumor T-cell immunity in patients with recurrent ovarian cancer.

The FDA has granted approval of rucaparib for maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

At SGO 2018, an early study showed ‘encouraging’ PFS with trastuzumab added to combination carboplatin/paclitaxel for advanced HER2/neu-overexpressing uterine serous carcinoma.

ACA Medicaid expansion benefited women younger than 65 who were diagnosed with a gynecologic cancer between 2011 and 2014, a SEER database analysis found.

An “ultra-restrictive” policy to reduce opioid prescribing to women who underwent major gynecologic cancer surgeries dramatically reduced opioid use.

A registry study suggests that there may be a familial association between ovarian and testicular cancers.

A large study found no association between the use of metformin or statins and the incidence of ovarian cancer in women with type 2 diabetes.

Lifastuzumab vedotin offered a modest improvement in progression-free survival over standard care in patients with platinum-resistant ovarian cancer.

A meta-analysis incorporating tens of thousands of individuals found no association between the use of antidepressants and the risk of epithelial ovarian cancer.

The novel agent prexasertib showed promising activity and was reasonably well tolerated in a phase II study of high-grade, heavily pretreated, BRCA wild-type serous ovarian carcinoma.